NCT02580539View on ClinicalTrials.gov

A Study of the Safety and Efficacy of EBV Specific T-cell Lines

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2025

Conditions
Epstein-Barr Virus InfectionsPost-Transplant Lymphoproliferative DisorderLymphoma
Interventions
BIOLOGICAL

Group A

Peptide-stimulated T cells 2 x 10\^7/m\^2

BIOLOGICAL

Group B

Peptide-stimulated T cells per dose-escalation protocol

Trial Locations (1)

H1T 2M4

Hôpital Maisonneuve-Rosemont, Montreal

All Listed Sponsors
lead

Dr. Jean-Sebastien Delisle, MD, PhD

OTHER

NCT02580539 - A Study of the Safety and Efficacy of EBV Specific T-cell Lines | Biotech Hunter | Biotech Hunter